Cited by 1,168Acute Ischemic Stroke ManagementAntiplatelet Therapy and Cardiovascular DiseasesAtrial Fibrillation Management and Outcomes

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke

Open access

Mohr, J.P., Thompson, J.L.P., Lazar, R.M., Levin, B., Sacco, R.L., Furie, K.L., Kistler, J.P., Albers, G.W., Pettigrew, L.C., Adams, H.P., Jackson, C.M., Pullicino, P.·2001·New England Journal of Medicine

DOI 10.1056/nejmoa011258

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Despite the use of antiplatelet agents, usually aspirin, in patients who have had an ischemic stroke, there is still a substantial rate of recurrence. Therefore, we investigated whether warfarin, which is effective and superior to aspirin in the prevention of cardiogenic embolism, would also prove superior in the prevention of recurrent ischemic stroke in patients with a prior noncardioembolic ischemic stroke. METHODS: In a multicenter, double-blind, randomized trial, we compared the effect of warfarin (at a dose adjusted to produce an international normalized ratio of 1.4 to 2.8) and that of aspirin (325 mg per day) on the combined primary end point of recurrent ischemic stroke or death from any cause within two years. RESULTS: The two randomized study groups were similar with respect to base-line risk factors. In the intention-to-treat analysis, no significant differences were found between the treatment groups in any of the outcomes measured. The primary end point of death or recurrent ischemic stroke was reached by 196 of 1103 patients assigned to warfarin (17.8 percent) and 176 of 1103 assigned to aspirin (16.0 percent; P=0.25; hazard ratio comparing warfarin with aspirin, 1.13; 95 percent confidence interval, 0.92 to 1.38). The rates of major hemorrhage were low (2.22 per 100 patient-years in the warfarin group and 1.49 per 100 patient-years in the aspirin group). Also, there were no significant treatment-related differences in the frequency of or time to the primary end point or major hemorrhage according to the cause of the initial stroke (1237 patients had had previous small-vessel or lacunar infarcts, 576 had had cryptogenic infarcts, and 259 had had infarcts designated as due to severe stenosis or occlusion of a large artery). CONCLUSIONS: Over two years, we found no difference between aspirin and warfarin in the prevention of recurrent ischemic stroke or death or in the rate of major hemorrhage. Consequently, we regard both warfarin and aspirin as reasonable therapeutic alternatives.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa011258

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,070
PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION
Petersen, P., GODTFREDSEN, J., Boysen, G., Andersen, E. D., & Andersen, B. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91200-2 · Cited by 1,814
The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial Fibrillation
The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators* (1990) · New England Journal of Medicine · doi:10.1056/nejm199011293232201 · Cited by 1,525
Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation
Ezekowitz, M. D., Bridgers, S. L., James, K. E., Carliner, N. H., Colling, C. L., Gornick, C. C., Krause-Steinrauf, H. J., Kurtzke, J. F., Nazarian, S. M., Radford, M. J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211123272002 · Cited by 1,204
A Randomized Trial Comparing Ticlopidine Hydrochloride with Aspirin for the Prevention of Stroke in High-Risk Patients
Hass, W. K., Easton, J. D., Adams, H. P., Pryse-Phillips, W. E. M., Molony, B. A., Anderson, S., Kamm, B., & for the Ticlopidine Aspirin Stroke Study Group (1989) · New England Journal of Medicine · doi:10.1056/nejm198908243210804 · Cited by 1,194
Self-citation
Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation
Barnes, D. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301143280227 · Cited by 1,072

Flagged first, then by citations

Show all 39 references

Research works printed but not linked: 4

1980, Lancet, 2, 989
Thompson JLP, 1994, Ann Neurol, 36, 305
10.2307/2281868 · DOI · Paper page
Mantel N, 1966, Cancer Chemother Rep, 50, 163

Sorted by citations

Items 901–999 of 999

Antithrombotic therapy for prevention of recurrent stroke in the new millenium
Schneck, M. J., & Biller, J. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.2.145 · Cited by 1
Oral Anticoagulation in Secondary Prevention After Cerebral Ischemia of Arterial Origin
Halkes, P. H. A. (2005) · Stroke · doi:10.1161/01.str.0000163821.57159.e0 · Cited by 1
A Glimpse of Canaan, 40 Years On
Mohr, J. P. (2009) · Cerebrovascular Diseases · doi:10.1159/000247024 · Cited by 1
“Sadly, aphasia and other features of higher cerebral function were deemed too arcane to pursue. The current emphasis on biostatistics, now in its ascendancy, has dwarfed former emphasis on the unusual case report in favor of the confidence intervals as the focus in manuscripts. No criticism intended, but case reports…”
BackgroundSelf-citation
Antiplatelet medications in the secondary prevention of ischemic stroke
Fleck, J. D. (2005) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-005-0015-2 · Cited by 1
“No difference between aspirin (325 mg/d) and warfarin (International Normalized Ratio of 1.4 to 2.8) was found in the prevention of recurrent IS or death or in the rate of major hemorrhage [ 9 ].”
BackgroundResultInfluential
Case 4—2005 Utility of Transesophageal Echocardiography in the Diagnosis of a Previously Undetected Atrial Septal Aneurysm With Shunt
Capdeville, M. J., Yang, S. X., Koch, C. G., & Reeves, S. T. (2005) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2005.04.009 · Cited by 1
Antiplatelet agents for secondary prevention of stroke
Bernstein, R. A. (2008) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-008-0024-y · Cited by 1
Transient Ischaemic Attacks
Madhavan, R., & Chaturvedi, S. (2003) · CNS Drugs · doi:10.2165/00023210-200317050-00001 · Cited by 1
Patent foramen ovale percutaneous closure: the no-implant approach
Butera, G., Romagnoli, E., Sangiorgi, G., Caputi, L., Chessa, M., & Carminati, M. (2008) · Expert Review of Medical Devices · doi:10.1586/17434440.5.3.317 · Cited by 1
Does transesophageal echocardiographic demonstration of a patent foramen ovale in patients with a recent cerebral ischemic event change anticoagulation therapy?
Boddicker, K. A., & Kerber, R. E. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2004.09.027 · Cited by 1
Combined Aspirin Plus Warfarin
Donnan, G. A., & Davis, S. M. (2009) · Stroke · doi:10.1161/strokeaha.108.537696 · Cited by 1
Caring for the Adult with Congenital Heart Disease: Management of Common Defects
Chugh, R. (2007) · The Permanente Journal · doi:10.7812/tpp/06-089 · Cited by 1
Current management of symptomatic intracranial stenosis: Medical versus endovascular therapy
Weigele, J. B., Taylor, R. A., & Kasner, S. E. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0036-1 · Cited by 1
“However, a randomized clinical trial showed that anticoagulation was no better than aspirin for secondary stroke prevention in patients with noncardioembolic stroke [ 18 ].”
Background
USE OF ANTICOAGULANT AGENTS FOR STROKE PREVENTION
Sloan, M. A. (2005) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000293709.69205.ed · Cited by 1
“The APASS study evaluated 1770 patients within the WARSS clinical trial (Levine et al, 2004).”
Background
Antithrombotic Therapy for Ischemic Stroke
Hah, J. S., & Lee, J. (2003) · Journal of Yeungnam Medical Science · doi:10.12701/yujm.2003.20.1.1 · Cited by 1
ESPRIT: Safety and Efficacy of Oral Anticoagulation—a Rebuttal
ESPRIT (2003) · Stroke · doi:10.1161/01.str.0000092203.74211.42 · Cited by 1
[Currently increasing cardiogenic cerebral embolism, especially in its prevention and treatment].
Iwamoto, T. (2005) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.42.504 · Cited by 1
Pharmacology and Clot: Immediate and Chronic Interventions
Kurz, M. A. (2008) · CRC Press eBooks · doi:10.3109/9781420020830-11 · Cited by 1
Medical treatment for carotid stenosis
Giles, M. F., & Rothwell, P. M. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544941.006 · Cited by 1
Antiplatelet Therapy
Schneck, M. J. (2004) · doi:10.1002/9780470988442.ch10 · Cited by 1
Pharmacology and Clot
Kurz, M. C. (2008) · CRC Press eBooks · doi:10.3109/9781420020830-9 · Cited by 1
OTHER ARTICLES NOTED (Nov 01 to 18 Oct 02)
(2003) · Evidence-Based Nursing · doi:10.1136/ebn.6.1.e1 · Cited by 1
A Practical Guide to Recurrent Stroke Prevention
Pedelty, L. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-010-6_11 · Cited by 1
“Anticoagulation with warfarin has not been shown to be superior to antiplatelet therapy in recurrent prevention of noncardioembolic stroke (58,85, 86 ), and in the absence of other indications, antiplatelet therapy is recommended over anticoagulation.”
Background
Use of Chronic Anticoagulation in the Elderly: A Review of the Benefits and Risks
O'Donnell, M. J. (2004) · Developments in cardiovascular medicine · doi:10.1007/978-1-4419-8865-2_9
Wertigkeit neuer kardiovaskulärer Biomarker zur Prädiktion kardiovaskulärer Ereignisse und der Mortalität bei Patienten mit akuter zerebraler Ischämie
Niehaus, C. (2013) · doi:10.53846/goediss-3902
Aterosclerosis intracraneal de gran vaso
Arenillas, J. F., Álvarez‐Sabín, J., Molina, C. A., & Puiggrós, A. C. (2004)
The selection of antithrombotic agents in the prevention of recurrent ischemic stroke
丹下, 恭. (2003) · Current Cardiology Reports · doi:10.1007/s11886-003-0083-3
“For those physicians who do use a parallel and sensitive testing technique for stroke pathogenesis diagnosis [2], it is unclear how to begin to apply the results of this study to recurrent stroke prevention [ 14 ].”
Method
Antithrombotic Therapy in Carotid and Peripheral Intervention
Helton, T. J., & Kapadia, S. R. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-235-3_15
Neurological Aspects of Caring for the Aged
Elkind, M. S. V. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-357-6_6
Cerebrovascular disease
Frankel, M., & Borland, D. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544590.035
Paradoxical embolism, migraine, and cardiac shunt closure
LUERMANS, J. G. L. M. (2010) · Utrecht University Repository (Utrecht University)
Elective Endovascular Revascularization of the Intracranial Cerebral Arteries
Strozyk, D., Schumacher, C., Meyers, P. M., & Higashida, R. T. (2011) · doi:10.1002/9781444329803.ch45
Secondary Stroke Prevention, and the Role of Antiplatelet Therapies
Kirshner, H. S. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2208
Secondary Stroke Prevention – Medical Treatment
Weber, R., & Diener, H. (2009) · KARGER eBooks · doi:10.1159/000210280
The Treatment of Established Complications: Cerebrovascular Disease
Brown, D. L., Hickenbottom, S. L., & Jacobs, T. L. (2010) · Wiley eBooks · doi:10.1002/9780470682807.ch22
Stroke, Epidemiological and Genetical Approach
Nadifi, S., & Hamzi, K. (2012) · InTech eBooks · doi:10.5772/33712
Treatment of Patients with Stroke
Anderson, C. S. (2002) · doi:10.1002/9780470986882.ch59
Tratamiento combinado con antitrombóticos en la prevención secundaria del ictus isquémico
Hernández, A. N. G., Pi, Ó. F., & Fernández, J. C. L. (2010) · Revista Médicas UIS
Chapter 9 Antithrombotic Therapy for Secondary Prevention of Ischemic Stroke
(2004) · Blue books of practical neurology · doi:10.1016/s1877-3419(09)70084-4
Intracranial Vertebral Artery Stenting
Rapp, J. A., Verma, A. K., & Collins, T. J. (2011) · Wiley eBooks · doi:10.1002/9781444329803.ch48
Transcatheter Occlusion of Atrial Septal Defects for Prevention of Recurrence of Paradoxical Embolism
Daraban, N., Reyes, M., & Richard, W. (2012) · InTech eBooks · doi:10.5772/48071
Role of Oral Anticoagulants
Chan, R., Chaturvedi, S., & Pullicino, P. M. (2004) · doi:10.1002/9780470988442.ch11
Self-citation
Antithrombotics for Ischemic Stroke
Nahab, F. B., & Qureshi, S. (2011) · Wiley eBooks · doi:10.1002/9781118067178.ch10
Chapter 20 Epidemiological implications of primary and secondary stroke prevention
Béjot, Y., & Giroud, M. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(08)01920-9
Carotid Stenosis: Primary Prevention and Medical Treatment
Pandele, G. I., & Dima‐Cozma, C. (2011) · doi:10.1002/9781444329803.ch12
Chapter 15 Treatment of Thrombosis in the Antiphospholipid Syndrome
Ruiz‐Irastorza, G., & Khamashta, M. A. (2009) · Technical report · doi:10.1016/s1571-5078(08)00415-7
Heparin and Related Compounds
Meschia, J. F. (2004) · doi:10.1002/9780470988442.ch12
Management of Carotid Artery Disease in the Setting of Coronary Artery Disease in Need of Coronary Artery Bypass Surgery
Aditya, M., & Herbert, D. (2013) · InTech eBooks · doi:10.5772/55669
Carotid Artery Stenosis Prevalence and Medical Therapy
Khurana, R., & Teal, P. A. (2009) · Contemporary cardiology · doi:10.1007/978-1-60327-314-5_1
“In patients without atrial fibrillation, presenting with TIA, or minor stroke, warfarin is not better than aspirin as a secondary prevention agent ( 49 ).”
Background
Chapter 7 Small-Vessel Occlusive Disease (Lacunar Stroke)
Benavente, O. (2004) · Blue books of practical neurology · doi:10.1016/s1877-3419(09)70082-0
Antiagregancia a antikoagulancia v prevenci a v léčbě cévních mozkových příhod
Goldemund, D., Mikulík, R., & Reif, M. (2007)
Cryptogenic Emboli and Other Elusive Causes of Stroke
Smirnakis, S. M., & Koroshetz, W. J. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-769-7_13
Disease Prevention and Screening
Taylor, R. B. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7874-5_4
Tratamiento médico de la estenosis arterial intracraneal. ¿Es el mismo en prevención primaria que secundaria?
Sieira, P. I., Fernández, M. R., & Martínez‐Vila, E. (2003) · Revista de Neurología · doi:10.33588/rn.3707.2003410
Management of Cryptogenic Strokes by Percutaneous Closure of Interatrial Communications
Manolis, A. S. (2009) · Hospital chronicles/Hospital Chronicles · doi:10.2015/hc.v4i4.195
“154 pharmacotherapy.(3,18-21) Certainly, one must emphasize that the PFO may simply serve in most cases as the passage gate of a right-sided thrombus to the systemic circulation leading to paradoxical embolism, and in very few one may suspect that there may be in situ thrombosis, particularly in large and long serpent…”
Background
Traitement des sténoses carotidiennes asymptomatiques : progression des idées, traitement médical, traitement chirurgical, quid de l’angioplastie ?
Age, B. (2004) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2003.09.008
Angiology: Diseases of the Blood Vessels
Adelmann, G. A. (2010) · Springer eBooks · doi:10.1007/978-1-84996-305-3_11
Ischaemic stroke in chagasic patients.
Teixeira, A. L., & Teixeira, M. M. (2004) · PubMed Central
Antithrombotic therapy in primary and secondary stroke prevention of cardiac patients and in acute stroke
Csiba, L., & Kovács, K. R. (2009) · Orvosi Hetilap · doi:10.1556/oh.2009.28414
Prothrombotic gene variation and cerebral ischaemia of arterial origin
Pruissen, D. M. O. (2002) · Utrecht University Repository (Utrecht University)
Neurointensive Care of the Acute Ischemic Stroke Patient
Badjatia, N., Nguyen, T. N., & Koroshetz, W. J. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-660-7_18
Faisabilité et résultats de la fermeture percutanée des foramens ovals perméables avec anévrisme du septum interauriculaire. Expérience du centre hospitalier général de Mulhouse
Roth, O., Jacquemin, L., Kénizou, D., Mettauer, B., & Monassier, J. P. (2007) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2007.08.004
Complications of stroke resulting from atrial fibrillation
Parmar, P., & Tolhurst, R. (2012) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2012.7.12.570
Faut-il prescrire une double antiagrégation plaquettaire après stenting artériel des membres inférieurs ? Le contre
Wahl, D. G. (2015) · Journal des Maladies Vasculaires · doi:10.1016/j.jmv.2014.12.126
Usefulness of Anticoagulants in the Prevention of Ischemic Stroke
Rubio, F., & Jato, M. (2003) · Cerebrovascular Diseases · doi:10.1159/000074798
Dolicoectasie arteriose intracraniche
Pico, F., Labreuche, J., Hauw, J., & Amarenco, P. (2008) · EMC - Neurologia · doi:10.1016/s1634-7072(08)70526-9
Enfermedad cerebrovascular (II): tratamiento, prevención secundaria y rehabilitación
Sardiña, M. D., Soidán, F. J. G., & Deibe, F. I. L. (2005) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(05)71310-4
Update on the Treatment of Systemic Lupus Erythematosus
Arango, A., & Reveille, J. D. (2006) · Women s Health · doi:10.2217/17455057.2.4.605
“Recently, the Antiphospholipid Antibodies and Stroke Study (APASS) data demonstrated that there was no difference in the risk of thrombotic events in patients treated with warfarin compared with aspirin-treated patients, with first ischemic stroke and a single positive antiphospholipid antibody test [46].”
Background
Tratamiento endovascular de estenosis intracraneales sintomáticas: resultados a corto y largo plazo de un único centro
Aparici, F., Tello, E. M., Vázquez-Añón, V., Lago, A. P., Parkhutik, V., & Ferrairó, J. T. (2012) · Radiología · doi:10.1016/j.rx.2011.11.008
Stroke News: Warfarin, Aspirin, Statins, IIb/IIIa Inhibitors, and Cilostazol TBA
Connors, J. J. “. (2003) · Journal of Vascular and Interventional Radiology · doi:10.1016/s1051-0443(03)70071-2
Les antithrombotiques dans la prévention des accidents ischémiques cérébraux
Bousser, M. (2005) · Journal des Maladies Vasculaires · doi:10.1016/s0398-0499(05)83843-0
“La grande étude américaine WARSS (Warfarin-Aspirin Reccurrent Stroke Study) (13) a comparé, en double aveugle, la warfarine (INR : 1,4-2,8) à l’aspirine : 325 mg/j chez des patients ayant eu un IC non cardioembolique dans le mois précédent ; 2 206 patients ont été inclus et suivis en moyenne 2 ans.”
Background
Acute Stroke Care
Zazulia, A. R., & Diringer, M. N. (2007)
Les antithrombotiques dans la prévention des accidents ischémiques cérébraux
Bousser, M. (2006) · Journal de Réadaptation Médicale Pratique et Formation en Médecine Physique et de Réadaptation · doi:10.1016/s0242-648x(06)70179-7
Prevention of embolism among patients with atrial fibrillation
Adams, H. P. (2005) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-005-0017-0
“Aims: The Stroke Prevention using Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF III) trial was an international, randomized, open-label clinical trial that tested oral ximelagatran or adjusted-dose warfarin in prevention of stroke or embolism among high-risk patients with atrial fibrillation [ 7 ].”
MethodSelf-citation
Risk adjustment in stroke research*
JOHNSTON, K. (2003) · Seminars in Cerebrovascular Diseases and Stroke · doi:10.1053/scds.2003.0017
Higher Prevalence of Patent Foramen Ovale Reported in Cryptogenic Stroke
Fallik, D. (2008) · Neurology Today · doi:10.1097/01.10149.0000309775.24899.fd
L’ordonnance de sortie après ischémie cérébrale
Rosolacci, T., & Neuville, V. (2005) · Revue Neurologique · doi:10.1016/s0035-3787(05)85133-1
Treatment options for intracranial arterial stenosis and progress of ongoing clinical trials
Chimowitz, M. M. I. (2003) · Seminars in Cerebrovascular Diseases and Stroke · doi:10.1053/scds.2003.00008
Complicaciones neurológicas en el síndrome antifosfolipídico: un asunto sin resolver
Canora, J., Largacha, M. G., & Mateo, E. M. M. (2004) · Medicina Clínica · doi:10.1016/s0025-7753(04)75323-3
Prevención de los accidentes cerebrovasculares
Béjot, Y., Giroud, M., & Touzé, E. (2011) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(11)70970-9
Sténoses athéroscléreuses carotides de la femme
Woimant, F. (2010) · La Presse Médicale · doi:10.1016/j.lpm.2009.03.021
Clinical trials of treatments for stroke
Blass, J. P. (2002) · Current Atherosclerosis Reports · doi:10.1007/s11883-002-0004-8
Impulsivity Reported in PD Patients with Deep Brain Stimulators
Talan, J. (2008) · Neurology Today · doi:10.1097/01.10149.0000309780.78263.fb
Current challenges of stroke treatment
Michel, P. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32833539c5
Medical prevention of secondary stroke: A cardiologist's perspective
Ezekowitz, M. D. (2004) · Clinical Cardiology · doi:10.1002/clc.4960271406
Clinical diagnosis of subcortical cerebral infarction
Gerraty, R. P. (2003) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.3.5.703
Endovascular treatment of symptomatic intracranial stenoses: Short- and long-term results in a single center
Aparici, F., Tello, E. M., Vázquez-Añón, V., Lago, A. P., Parkhutik, V., & Ferrairó, J. T. (2013) · Radiología (English Edition) · doi:10.1016/j.rxeng.2011.11.005
“Management of IAS has a better prognosis with antiaggregant drugs than anticoagulants.(3,4) It was believed that aggressive treatment with double antiaggregation was little effective in the long run in high-degree stenosis (>70%),(15) which could benefit from invasive therapies.”
Background
Foramen ovale perméable : quand intervenir ?
Juliard, J., & Deslée, G. (2007) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(07)91802-1
Incidence of Newly Detected Atrial Arrhythmias Through Implantable Devices in Patients With a History of Thromboembolic Events
Willey, J. Z. (2010) · Stroke · doi:10.1161/strokeaha.110.584250
Craniocervical large-artery occlusive disease in the spectrum of ischemic cerebrovascular disease
Blacker, D., & BROWNJR, R. (2002) · Seminars in Cerebrovascular Diseases and Stroke · doi:10.1053/scds.2002.130312
ESPRIT: The European/Australian stroke prevention in reversible ischaemia trial
DESCHRYVER, E., & Algra, A. (2003) · Seminars in Cerebrovascular Diseases and Stroke · doi:10.1053/seds.2003.00007
10 Most Commonly Asked Questions About Which Antiplatelet Agent To Prescribe
Adams, H. P. (2003) · The Neurologist · doi:10.1097/01.nrl.0000094629.03562.8f
Self-citation
So, What’s New?
Kuller, L. H. (2007) · Stroke · doi:10.1161/strokeaha.106.480459
Regarding “standards of practice: Carotid angioplasty and stenting”
Durham, J. D., Sacks, D., & Connors, J. J. “. (2004) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2004.07.019
Noncardioembolic Ischemic Stroke? Reasonable Therapeutic Alternative to Aspirin for Preventing Recurrent Warfarin-Aspirin Recurrent Stroke Study (WARSS) Trial : Is Warfarin Really a
Hankey, G. J. (2012)
Antithrombotic Therapy in Secondary Stroke Prevention
Akhtar, N., Deleu, D., & Shuaib, A. M. (2006) · Aging Health · doi:10.2217/1745509x.2.5.787
“5–3) among 2206 patients [21].”
Patent foramen ovale and cryptogenic stroke: is there still a role for percutaneous closure?
Spies, C., & Hijazi, Z. M. (2012) · Clinical Practice · doi:10.2217/cpr.12.80
LC-MS/MS analysis of drug dosage and genetic polymorphism in patients on anti-coagulant warfarin treatment : potential in biomarker identification
Sadrolodabaee, L. (2009) · doi:10.32657/10356/47461
Cryptogenic stroke and PFO diagnosis
Juliard, J. M., Aubry, P., Mazighi, M., Brochet, É., Charlier, P., Enguerand, D., Berroëta, C., Lepage, L., Vahanian, A. S., & Amarenco, P. (2007) · International Cardivascular Research Journal
ESPRIT (European/Australasian Stroke Prevention in Reversible Ischaemia Trial) and related studies
Halkes, P. H. A. (2004) · Utrecht University Repository (Utrecht University)

Authors: Mohr, J. P., Thompson, J. L. P., Lazar, R. M., Levin, B., Sacco, R. L., Furie, K. L., Kistler, J. P., Albers, G. W., Pettigrew, L. C., Adams, H. P., Jackson, C. M., & Pullicino, P.
Affiliations: Columbia University Irving Medical Center (US)
Massachusetts General Hospital (US)
Stanford Medicine (US)
University of Kentucky (US)
University of California San Diego (US)
University at Buffalo, State University of New York (US)
ORCID: Mohr, J.P.
Thompson, J.L.P.
Lazar, R.M.
Sacco, R.L.
Furie, K.L.
Albers, G.W.
Pettigrew, L.C.
Adams, H.P.
Pullicino, P.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2001-11-15
Volume: 345
Issue: 20
Pages: 1444-1451
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa011258
OpenAlex: W2027538725
Cited by: 1,168
References: 39
Citations by year: 2026: 9 · 2025: 12 · 2024: 13 · 2023: 22 · 2022: 20 · 2021: 40 · 2020: 24 · 2019: 37 · 2018: 32 · 2017: 33 · 2016: 50 · 2015: 41 · 2014: 54 · 2013: 39 · 2012: 49
FWCI: 54.22
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Kent Academic Repository (University of Kent) (submittedVersion)
Funders: U.S. Department of Veterans Affairs
Yale University
University of Southern California
Vanderbilt University
University of Miami
Wayne State University
Cleveland Clinic
Cleveland Clinic Foundation
Johns Hopkins University
Hennepin County Medical Center
University of South Alabama
York University
University of Illinois at Urbana-Champaign
National Institute of Neurological Disorders and Stroke (R01NS028371)
Topics: Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Keywords: warfarin, aspirin, recurrent ischemic stroke, secondary stroke prevention, antiplatelet therapy, major bleeding, non-cardioembolic stroke, lacunar infarction, cryptogenic stroke, international normalized ratio, anticoagulation
MeSH terms: Adult, Aged, Aged, 80 and over, Anticoagulants, Aspirin, Brain Ischemia, Double-Blind Method, Female, Hemorrhage, Humans, Male, Middle Aged, Mortality, Platelet Aggregation Inhibitors, Risk Factors, Warfarin, International Normalized Ratio, Stroke, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks